Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and support a Phase I trial of CBX‑250, a novel T‑cell engager targeting relapsed and refractory myeloid malignancies including AML and MDS. CEO Briggs Morrison said the financing will also back a nominated second candidate, CBX‑663, and IND filings planned for spring 2026. The round highlights investor interest in TCR‑mimicking antibodies that target peptide‑HLA complexes to reach intracellular tumor drivers; Crossbow is positioning its T‑Bolt molecules to expand antibody reach beyond surface antigens. The funding aims to drive clinical staging and broaden the company’s pipeline.